Dialysis provider DaVita Inc. (NYSE: DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.
Is now the time to buy DVA? Find out in our full research report (it’s free for active Edge members).
DaVita (DVA) Q3 CY2025 Highlights:
- Revenue: $3.42 billion vs analyst estimates of $3.43 billion (4.8% year-on-year growth, in line)
- Adjusted EPS: $2.51 vs analyst expectations of $3.17 (20.9% miss)
- Adjusted EBITDA: $722.2 million vs analyst estimates of $750.6 million (21.1% margin, 3.8% miss)
- Management reiterated its full-year Adjusted EPS guidance of $10.75 at the midpoint
- Operating Margin: 14.8%, down from 16.4% in the same quarter last year
- Sales Volumes fell 1.5% year on year (0.6% in the same quarter last year)
- Market Capitalization: $9.05 billion
StockStory’s Take
DaVita’s third quarter results drew a negative reaction from the market, as the company’s profit and margins fell short of analyst expectations despite meeting revenue forecasts. Management attributed the underperformance primarily to lower treatment volumes, which declined due to a combination of a severe flu season, the impact of Hurricane Helene, and disruptions from a cyber incident. CEO Javier Rodriguez highlighted ongoing cost management and continued investment in clinical innovation, but acknowledged that these headwinds weighed on the company’s operational results. As Rodriguez noted, “U.S. treatment volume was down approximately 1.5% year-over-year,” underscoring the pressures facing DaVita’s core dialysis business.
Looking ahead, DaVita’s guidance for the remainder of the year and beyond is shaped by lingering uncertainty in treatment volumes, payer mix, and policy decisions that could affect insurance coverage. Management is closely monitoring developments around federal premium tax credits and shifts in Medicare Advantage enrollment, both of which could meaningfully impact revenue composition next year. While Rodriguez reaffirmed the company’s guidance targets, he emphasized that “a range of potential outcomes for 2026” remains, with open enrollment and payer dynamics as major variables. DaVita’s investments in technology and clinical protocols are expected to drive efficiency and eventually support improved patient outcomes, but their financial impact may take time to materialize.
Key Insights from Management’s Remarks
Management pointed to specific operational and external factors that drove the quarter’s results, with additional attention given to technology investments and industry policy shifts.
-
Volume headwinds from external events: DaVita saw a notable decline in U.S. treatment volumes, which management attributed to a severe flu season, Hurricane Helene, and a cyber incident disrupting patient admissions and treatment continuity. These one-time events represented a 75 to 100 basis point headwind for the quarter’s volume growth.
-
Cost discipline offset by wage and drug pressures: While patient care costs per treatment increased, mainly due to higher wages and pharmaceutical expenses, management noted that cost controls outside of these items continued to outperform initial expectations.
-
Investments in technology and AI: The company is upgrading scheduling and revenue operations systems and rolling out artificial intelligence solutions to streamline administrative tasks and improve collections. These investments have led to higher general and administrative expenses but are aimed at long-term efficiency gains.
-
Payer mix volatility and policy uncertainty: Active policy debates around federal premium tax credits and the ongoing recalibration of the Medicare Advantage landscape were cited as significant sources of uncertainty affecting revenue per treatment and insurance mix.
-
Integrated Kidney Care (IKC) timing impacts: Timing of revenue recognition in DaVita’s value-based care business, IKC, proved unpredictable, with payment timing from government programs and payers affecting quarterly results. Management expects further variability in this area, which will continue to influence profitability.
Drivers of Future Performance
Management expects future performance to be shaped by policy changes, technology adoption, and ongoing challenges in treatment growth and payer mix.
-
Treatment volume recovery uncertain: Management flagged that while some 2025 headwinds, such as the flu season and cyber event, are not expected to recur, underlying volume growth remains challenged. Efforts to improve clinical outcomes and patient retention could be gradual, with Rodriguez explaining that mortality improvements “take time.”
-
Payer mix and insurance policy risks: The fate of federal premium tax credits and ongoing shifts in Medicare Advantage enrollment could significantly affect DaVita’s commercial mix and revenue per treatment. CFO Joel Ackerman stressed that commercial mix is a larger financial swing factor than Medicare Advantage, and policy decisions could drive material changes in payer composition.
-
Efficiency gains from technology initiatives: Continued investment in clinical platforms, administrative automation, and AI-driven processes are intended to enhance efficiency and collections. While these projects are expected to yield benefits over time, management cautioned that the impact on volume and profitability is difficult to quantify in the near term.
Catalysts in Upcoming Quarters
In the coming quarters, key areas to watch include signs of stabilization or improvement in U.S. dialysis treatment volumes, policy developments around federal premium tax credits and Medicare Advantage enrollment that could shift the payer mix, and measurable progress in efficiency gains from technology and operational initiatives. Additionally, the timing and recognition of revenue in the Integrated Kidney Care segment will remain a significant area of variability.
DaVita currently trades at $123.50, down from $126.50 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
